The interaction between NKG2A and human leukocyte antigen‐E (HLA‐E) serves to inhibit the activation of NK cells and T cells, and interrupting this interaction has been shown to enhance tumor immune response [27, 28]. Here, KLRC1 is linked to neoplasm.